Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel
Kamada completed manufacturing of the first batch of its plasma-derived IgG product for COVID-19 utilizing the Company’s approved proprietary IgG platform technology, and additional production is ongoing. The initial vials are available for compassionate use in Israel. In addition, Kamada’s proposed clinical protocol for a Phase 1/2 clinical trial was submitted to the Israeli Ministry of Health, and the Company expects to initiate the study during the third quarter of this year.
Read MoreCoronavirus pandemic: Red Cross' free COVID antibody testing provides incentive to donate blood
With more people undergoing elective surgeries, the American Red Cross is dealing with an urgent need for blood donations.
Read MoreResearchers identify potent antibody cocktail to treat COVID-19
Researchers evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19.
Read MoreCOVID-19: Urgent plea for plasma as Sarasota hospital sees uptick in hospitalizations
Amid an uptick in cases, a Sarasota hospital is treating more coronavirus patients and local blood banks are running dangerously low on what they need to treat them.
Read MoreFresno County wants recovered COVID-19 patients to donate blood, plasma
With Fresno County at just over 2,700 total COVID-19 cases, it's now on the governor's list to receive more targeted engagement from state officials.
Read MoreSan Antonio doctor who survived COVID-19 saving lives with his plasma
Dr. Aaron King among elite group of blood donors at the South Texas Blood and Tissue Center
Read More